Working… Menu

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03126110
Recruitment Status : Active, not recruiting
First Posted : April 24, 2017
Last Update Posted : July 21, 2020
Information provided by (Responsible Party):
Incyte Corporation ( Incyte Biosciences International Sàrl )

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : April 28, 2021
Estimated Study Completion Date : October 28, 2021